Detailed price information for Verastem Inc (VSTM-Q) from The Globe and Mail including charting and trades.
Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.
Verastem Oncology reports promising VS-7375 response rates in pancreatic, colorectal, and lung cancers, with a Phase 3 trial planned for 2026.
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.
Verastem (VSTM) shares jump on VS-7375 KRAS G12D data: up to 50% ORR in 2L pancreatic cancer at 900 mg.
Verastem Oncology (NASDAQ:VSTM) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and
The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.
Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor. Learn why VSTM stock is a buy.
This is the newest page. Registered accounts read further back.